Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience.
Based on the encouraging results of transplantation in animals with experimental autoimmune encephalomyelitis (EAE), small-scale phase I/II trials of autologous hematopoietic stem cell transplantation (autoHSCT) were initiated in 1995 for the treatment of severe cases of multiple sclerosis (MS). More than 200 patients with treatment-resistant multiple sclerosis have been transplanted so far, mainly in Europe and the USA. The results of these studies appear promising in terms of impact on MRI disease parameters and, to a lesser extent, clinical stabilization or even improvement. Despite concerns raised by the morbidity and mortality noted in the initial pilot studies, a controlled, randomized, phase III trial of autoHSCT against the best currently available treatment, i.e., mitoxantrone, seems justified and is under way.
Fassas
Athanasios
A
Department of Hematology and Bone Marrow Transplantation Unit, George Papanicolaou Hospital, 57010 Exokhi, Thessaloniki, Greece. hempap@otenet.gr
Kimiskidis
Vasilios K
VK
D002986:Clinical Trials as Topic / Q000706:statistics & numerical data / Q000639:trends; D018450:Disease Progression; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000639:trends; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D014182:Transplantation, Autologous / Q000379:methods* / Q000639:trends; D016896:Treatment Outcome
D008942:Mitoxantrone